Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Saeki

Showing results (181-190 of 186) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 186 results.
The Japanese Journal of Antibiotics|May 12, 1998
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)]J Igari, M Inoue, T Nishino, et al.
The Japanese Journal of Antibiotics|July 9, 1999
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)]J Igari, T Shibano, S Satou, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|November 12, 2020
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology|January 4, 2021
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The Japanese Journal of Antibiotics|June 2, 2000
[Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents]J Igari, N Watanabe, N Uehara, et al.
Pageof 19

Showing results (181-190 of 186) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 186 results.
The Japanese Journal of Antibiotics|May 12, 1998
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)]J Igari, M Inoue, T Nishino, et al.
The Japanese Journal of Antibiotics|July 9, 1999
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)]J Igari, T Shibano, S Satou, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|November 12, 2020
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology|January 4, 2021
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The Japanese Journal of Antibiotics|June 2, 2000
[Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents]J Igari, N Watanabe, N Uehara, et al.
Pageof 19